UNSPSC 51311703: Quifenadine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9A18RJ49B, chemically known as 3-quinuclidinemethanol, alpha,alpha-diphenyl- but generally known as quifenadine, which bears US NIH Compound Identifier 65600. European Medicines Agency schedules Quifenadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10193MIG.

UNSPSC 51311703 Quifenadine, a Commodity code, does not map accurately to the state and local procurement activity recently posted under this code. The three opportunities posted in the past six months—including a Seminole County naloxone and drug-deactivation-system procurement, a Texas HHS therapeutic pharmacy initiative RFI, and a Minnesota multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products—involve broadly distributed pharmaceutical and OTC product procurement, not the specific antihistamine compound the code nominally designates. The issuing bodies are primarily state health and human services agencies and county health departments seeking to establish supply relationships for medication distribution and pharmacy benefit management, rather than procurement of quifenadine as a distinct product line.

Recent activity shows state and local buyers sourcing through cooperative purchasing vehicles and direct-to-wholesaler channels. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 drug-deactivation systems annually with quarterly deliveries to the County Community Health Building. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) in April 2026 on direct-to-manufacturer prescription programs to inform future procurement strategy. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with awarded vendors distributed to AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson wholesalers. Given the mismatch between the code's nominal pharmaceutical scope and actual recent procurement activity spanning diverse medication classes and delivery models, the code itself shows limited relevance as a targeting tool for pursuing quifenadine-specific opportunities.